Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.06 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.05 -0.01 (-0.94%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 241 - 260 ( 386 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Reports 4Q18 Results; Selinexor PDUFA April 6
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology - AACR Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
FDA AdCom Meeting Strikes Down Selinexor, Eyes Ahead to BOSTON
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ODAC Recommends the FDA Wait for Phase 3 BOSTON Data Before Deciding on KaryopharmÂ’s Selinexor Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Bad Briefing Docs Arising, Trouble on the Way?
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Model Update; Maintaining $30 PT, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ODAC Panel to Discuss KaryopharmÂ’s Selinexor NDA Filing on February 26, 2019
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Announces Selinexor MAA Submission to EMA in Multiple Myeloma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
ASH 2018: Key Presentations Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm Presents Strong Phase 2b STORM and SDd Data in MM at ASH 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Topline SADAL Paves Way for 1H19 sNDA filing in DLBCL, Potential AA
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive Data for Phase 2b SADAL and Selinexor SPd at ASH 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology - Holiday Discounts Continue: Highlighting Buying Opportunities within Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Karyopharm 3Q18 Results; Positive Selinexor Progress and Platform Updates
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E